<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639703</url>
  </required_header>
  <id_info>
    <org_study_id>ISO-44-013</org_study_id>
    <nct_id>NCT01639703</nct_id>
  </id_info>
  <brief_title>Hepatic Xenetix-CT Perfusion</brief_title>
  <official_title>Diagnostic Contribution of XENETIXÂ® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT
      perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC)
      and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the
      aim to cover the entire liver.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perfusion parameters and histology grade</measure>
    <time_frame>within a week before surgery</time_frame>
    <description>Correlation between perfusion parameters and histology grade using CT perfusion exam and pathology findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT perfusion parameters and histopathology data</measure>
    <time_frame>within a week before surgery</time_frame>
    <description>Correlation between ct perfusion parameters and histopathology data using CT perfusion exam and pathology findings Histopathology data will be: some immunohistochemistry parameters, HCC phenotype, microvessel density and some angiogenic factors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CT perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arm with CT perfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Xenetix-CT perfusion imaging</intervention_name>
    <description>Injection of 50 ml of Xenetix</description>
    <arm_group_label>CT perfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed for HCC and planned for surgery (lobectomy or transplantation)
             within a timeframe of 30 days between first imaging procedure used for the study and
             surgery.

        Exclusion Criteria:

          -  Subjects who have undergone prior TACE (TransArterial Chemo Embolization), prior RFA
             (Radio Frequency Ablation) or prior SIRT (Selected Internal Radio Therapy) within one
             year before inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem Alkadhi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zurich University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMC</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNUH</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zurich University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Korea, Republic of</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 23, 2014</lastchanged_date>
  <firstreceived_date>July 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CT perfusion</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Xenetix</keyword>
  <keyword>Contrast agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
